DPP4 抑制剂与 COVID-19：圣杯还是死胡同？
DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?
机构信息
Department of Histology and Embryology, Medical University of Warsaw, Chalubinskiego 5, 02-004, Warsaw, Poland.
Department of Pediatric Pulmonology and Allergy, Medical University of Warsaw, Warsaw, Poland.
出版信息
Arch Immunol Ther Exp (Warsz). 2021 Feb 2;69(1):1. doi: 10.1007/s00005-020-00602-5.
A novel coronavirus disease, COVID-19, has emerged as a global public health issue. Clinical course of disease significantly correlates with the occurrence of some comorbidities, among them type 2 diabetes. According to recent structural studies the dipeptidyl peptidase 4, a key molecule in the pathophysiology of diabetes, may influence the course of COVID-19. Since DPP4 inhibitors, gliptins, are widely used in diabetes patients, the exact role of DPP4 modulation in SARS-CoV-2 infection, at least in that group, urgently needs to be clarified. In this short review, we discuss this issue with more detail.
一种新型冠状病毒疾病，COVID-19，已成为全球公共卫生问题。疾病的临床过程与一些合并症的发生显著相关，其中包括 2 型糖尿病。根据最近的结构研究，二肽基肽酶 4（糖尿病病理生理学中的关键分子）可能会影响 COVID-19 的病程。由于二肽基肽酶 4 抑制剂（gliptins）在糖尿病患者中广泛使用，因此二肽基肽酶 4 调节在 SARS-CoV-2 感染中的作用（至少在该人群中）急需阐明。在这篇简短的综述中，我们更详细地讨论了这个问题。
Zotero 插件